Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

Cancer Clinical Trial

Official title:

Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02306135
• Other study ID #: D15036
• Status: Terminated
• Phase: N/A
• First received: December 1, 2014
• Last updated: April 25, 2016
• Start date: March 2015
• Est. completion date: March 2016

Study information

• Verified date: January 2016
• Source: Dartmouth-Hitchcock Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Data and Safety Monitoring Board
• Study type: Observational [Patient Registry]

Clinical Trial Summary

mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the treatment of ER+/HER2- breast cancer (in combination with exemestane), renal cell carcinoma, subependymal giant cell astrocytoma (SEGA), and neuroendocrine tumors of pancreatic origin (PNET), and is currently being tested in ongoing clinical studies in other indications. While everolimus-based therapies elicit anti-cancer effects, most cancers ultimately progress and exhibit everolimus resistance. This study will evaluate genetic mechanisms of resistance to everolimus.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: March 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Treatment with everolimus (as a single-agent or in combination) for any malignancy for =3 months.

2. A- Patients who are scheduled to undergo a clinically indicated tumor biopsy (as standard of care, or as part of another study) within 5 years following cancer progression on everolimus are eligible.

B- Patients who already had such a biopsy procedure performed are eligible. Tumors biopsied shortly after progression on everolimus are strongly preferred.

3. Excess tumor tissue from biopsy must be available for molecular analysis. This will include tumor tissue sufficient to make =5 five-micron sections; more tumor tissue is preferred.

4. Patients currently seen at Dartmouth-Hitchcock Medical Center must be capable and willing to provide informed written consent for study participation. Patients who are no longer seen at DHMC will not be consented for use of archived tissues and data.

5. For patients currently seen at Dartmouth-Hitchcock Medical Center, patients must be willing to provide an extra 10-20 mL of blood during a routine, clinically indicated blood draw procedure.

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cancer

Intervention

Other:
• n/a- this is an observational study

Locations

Country	Name	City	State
United States	Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire

Sponsors (1)

Lead Sponsor	Collaborator
Dartmouth-Hitchcock Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mutations in genes encoding components of the mTOR pathway that are detected in post-everolimus tumors but not pre-everolimus tumors.		1 year	No
Secondary	Mutations detected in plasma DNA that are present in the post-everolimus tumor but not the pre-everolimus tumor.		1 year	No